Sarda Proteins Ltd will consider raising its authorised equity share capital to ₹100 crore in a board meeting scheduled for July 4, 2026. The proposal seeks to increase the capital from the existing ₹13 crore, a move aimed at expanding the company's financial base for future requirements. The board will also deliberate on altering the object clause of the Memorandum of Association to align with potential business expansion strategies.

The meeting, convened pursuant to Regulation 29 of the SEBI (LODR) Regulations, 2015, will see the board approve the draft notice for an Extraordinary General Meeting (EGM). Shareholders will be voting on the proposed capital increase and alterations to the Memorandum of Association. The board is also scheduled to appoint a scrutinizer to oversee the voting process during the EGM.

Key Agenda Items

The board meeting will focus on four primary resolutions:

• Increase in Authorised Capital: Raising the limit from ₹13,00,00,000 to ₹1,00,00,00,000.
• Alteration of MOA: Modifying the object clause to reflect new business objectives.
• EGM Notice: Approval of the draft notice to convene the Extraordinary General Meeting.
• Scrutinizer Appointment: Selecting an official to conduct the postal ballot or e-voting process.

Financial Implications

The decision to enhance the authorised capital indicates the management's intent to raise equity funds in the near future. While the current authorised capital stands at ₹13 crore, the proposed increase to ₹100 crore provides the necessary headroom for issuing new shares. This strategic step is often taken to facilitate funding for acquisitions, debt reduction, or capital expenditure.

The intimation was submitted to BSE Limited by Chirag Thummar, Managing Director of Sarda Proteins Ltd. The filing confirms that the meeting will be held to finalize the procedural requirements for the EGM, ensuring compliance with regulatory standards.

The Committee of Independent Directors (IDC) of Sarda Proteins Limited has unanimously recommended that the open offer by Onix Renewable Limited to acquire up to 19.28% of the company's share capital is fair and reasonable. The offer, priced at ₹115.00 per fully paid-up equity share, was triggered pursuant to Regulations 3(1) and 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the conversion of warrants into equity shares on March 18, 2026. The IDC, comprising Dhairyakumar Mohanbhai Thakkar and Chintan Umeshbhai Shatt, reviewed the Public Announcement, Detailed Public Statement, and Letter of Offer before arriving at this conclusion.

Offer Parameters

The open offer seeks to acquire 17,30,400 equity shares, representing 19.28% of the Emerging Voting Share Capital. The offer price of ₹115.00 is at par with the negotiated price paid during the conversion of warrants and is higher than the volume-weighted average market price for the 60 trading days preceding the Public Announcement, which was ₹72.94 on the BSE. The shares of Sarda Proteins Limited are listed on the BSE under the XT Group and are currently suspended from trading on the Calcutta Stock Exchange.

Key Financial and Regulatory Details

The offer is managed by Grow House Wealth Management Private Limited. The IDC confirmed that its members hold no equity shares in the target company or the acquirer and have no other contractual relationships. The committee advised shareholders to independently evaluate the offer against the current market price before participating. The recommendation was published in national and regional newspapers, including the Financial Express and Jansatta, on June 08, 2026.